Literature DB >> 27509590

Peritoneal dialysis treatment of metformin-associated lactic acidosis in a diabetic nephropathy patient
.

Jianjun Gao, Zhaoyan Gu, Yongxing Xu, Yu Na.   

Abstract

We report a case of metformin-associated lactic acidosis (MALA) in a 66-year-old man with end-stage renal disease on peritoneal dialysis (PD). The patient presented with severe lactic acidosis and was treated successfully with automated peritoneal dialysis (APD). During the treatment, PD solution was prepared from hemofiltration substitute fluid. The prescription was 8 cycles of 2,000 mL over 24 hours with the prepared solution, and venoclysis with sodium bicarbonate to improve the acidosis. After 3 days of treatment, his lactic acidosis was corrected. This case demonstrated that PD using hemofiltration substitute fluid is an option for patients with MALA.
.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27509590     DOI: 10.5414/CN108859

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  3 in total

1.  Is the use of metformin in patients undergoing dialysis hazardous for life? A systematic review of the safety of metformin in patients undergoing dialysis.

Authors:  Christina Abdel Shaheed; Jane E Carland; Garry G Graham; Sophie L Stocker; Greg Smith; Mark Hicks; Kenneth M Williams; Timothy Furlong; Peter Macdonald; Jerry R Greenfield; Felicity C Smith; Gina Chowdhury; Richard O Day
Journal:  Br J Clin Pharmacol       Date:  2019-12-09       Impact factor: 4.335

2.  The Association between Metformin Therapy and Lactic Acidosis.

Authors:  Isabelle H S Kuan; Ruth L Savage; Stephen B Duffull; Robert J Walker; Daniel F B Wright
Journal:  Drug Saf       Date:  2019-12       Impact factor: 5.606

3.  Astragalus polysaccharides protect renal function and affect the TGF-β/Smad signaling pathway in streptozotocin-induced diabetic rats.

Authors:  Xue Meng; Mingmin Wei; Dong Wang; Xiaohan Qu; Kun Zhang; Nan Zhang; Xinjian Li
Journal:  J Int Med Res       Date:  2020-05       Impact factor: 1.671

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.